Ozempic and Wegovy price cuts: what the numbers actually mean for UK patients

What official guidance and pricing data actually tell us

Ozempic and Wegovy both contain semaglutide, but they are authorised for different purposes under UK law. The cost distinction between Ozempic and Wegovy is partly a function of how each product is licensed: Ozempic carries a UK marketing authorisation for type 2 diabetes, while Wegovy's authorisation covers weight management. The MHRA regulates them separately, and NHS guidance on semaglutide is clear that using a diabetes product for weight loss is not the same as receiving the licensed weight-management treatment.

On the private market, Wegovy prices in the UK have moved as Novo Nordisk has adjusted supply and as the competitive landscape around tirzepatide has shifted. Reported private prices across providers have ranged roughly £149 to £375 per month depending on dose and provider, though these figures vary and are best treated as a general reference rather than a guarantee. Eli Lilly's decision to raise Mounjaro's list price from around £122 to around £330 per four-week pen from 1 September 2025 reset expectations across the sector, and Wegovy pricing has been talked about in similar terms. What the headlines rarely explain is that the pen price is only one input into the final cost a patient pays.

The NICE appraisal of semaglutide for weight management, TA875, sets the clinical threshold and population criteria but says nothing about private list prices. Price-cut news is manufacturer-level; whether any saving reaches the patient depends entirely on how a provider has structured its service.

What headline prices tend to leave out

A quoted per-pen price often does not include the consultation, the prescription, the clinical review that must accompany every supply of a prescription-only medicine, or the aftercare that responsible providers build in. Some services charge separately for each of those components, which can add meaningfully to the figure advertised. Others bundle aftercare and follow-up loosely, with no clear commitment to clinical re-review before a repeat. That structure can look cheaper at first glance and cost more by the second month, once prescription fees and delivery are added. How Wegovy is priced across the private market covers this in more detail.

There is also the supply-chain question. Genuine Wegovy comes through the licensed UK supply chain via Novo Nordisk-authorised routes. A price that sits well below the market range may reflect a supply source that cannot be verified. The MHRA has warned publicly and repeatedly about fake weight-loss pens being sold online, including counterfeit pens that contained the wrong medicine entirely. A quick check anyone can do in under a minute: visit the GPhC pharmacy register, type in the pharmacy's name, and confirm it holds a valid UK registration. If it does not appear, that is a firm red flag before any money changes hands.

Discount codes offered for prescription medicines are worth treating with particular caution. Comparing costs across semaglutide products gets harder when some listed prices are promotional rates that will not persist, or that attach conditions around eligibility that are explained only in the small print.

What is actually licensed for weight loss in the UK, and where to look

Ozempic is not licensed for weight loss in the UK. Prescribing it for that purpose is off-label, which a GP may do in specific clinical circumstances but which a regulated weight-management service should not do routinely, and which no responsible pharmacy should promote as an equivalent to Wegovy. Patients searching for Ozempic price cuts in a weight-management context are often looking for Wegovy, or for the newer dual-agonist treatment tirzepatide, which is sold as Mounjaro, and whether Ozempic actually works out cheaper than Wegovy is a question worth reading through carefully before drawing any conclusions. Both Wegovy and Mounjaro hold full UK marketing authorisations for weight management and are the medicines dispensed by regulated services. Wegovy's UK licence, trial results and eligibility criteria are covered on our Wegovy information page.

At nume, the treatments available through a private prescription following clinical assessment are Wegovy and Mounjaro. A named GPhC-registered Independent Prescriber reads every consultation; no automated system makes the approval decision. Exploring the treatment options alongside clinical guidance from our prescribers is the right starting point if you are weighing up which medicine suits your circumstances. Details of our clinical team are on our clinical leadership page.

Why cheapest is the wrong question when the stakes involve a prescription medicine

The honest position from a clinical standpoint is that price is not a safe primary filter for a prescription medicine. A service priced below the market may have cut corners on the clinical review, sourced outside the licensed supply chain, or is offering a promotional rate that will rise sharply on the next order. None of those outcomes saves the patient money in any meaningful sense. Legitimate clinical assessment, a verified supply chain, and genuine aftercare have a cost, and that cost belongs in the price.

Cheapest is not a race we entered deliberately. The price at which nume — sorry, at which a service operates reflects what is included: a free consultation, a clinical prescription review, the medicine, next-working-day tracked delivery, and aftercare access seven days a week, all in a single figure with no hidden extras and no subscription. Understanding the semaglutide content in different products can help readers make a properly informed comparison rather than a price-led one. For a detailed look at what to expect when you start, our FAQs page covers the most common questions we hear from patients. When you are ready to see whether you meet the clinical criteria, check your eligibility with our prescribers.